Vimal Mehta, CEO, President & Secretary at BioXcel Therapeutics, Inc. (BTAI), bought 1,000 shares at $8.75 ($9K) on 2019-08-13, disclosed to the SEC on 2019-08-14.
Open-market purchase of $9k BTAI by CEO, President & Secretary. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |
| BTAI | SELL | 2024-09-17 | $1K | — | Filing → |
| BTAI | SELL | 2024-06-18 | $3K | — | Filing → |
| BTAI | SELL | 2024-04-08 | $14K | — | Filing → |